CompoundsActive IngredientsBrivaracetam CAS 357336-20-0

SKU: WGP-357336-20-0




Brivaracetam, a novel oral antiepileptic drug with a high affinity for synaptic vesicle protein 2A (SV2A), was approved in Europe and the US as an adjunctive therapy for the treatment of partial onset seizures with or without secondary generalization in patients aged 16 or older.

  • Description
  • Additional information


Brivaracetam CAS 357336-20-0 Product Information

Product Name: brivaracetam
Synonyms: (alphaS,4R)-alpha-Ethyl-2-oxo-4-propyl-1-pyrrolidineacetamide;UCB-34714;1-PyrrolidineacetaMide, α-ethyl-2-oxo-4-propyl-, (αS,4R)-;(S)-2-((R)-2-oxo-4-propylpyrrolidin-1-yl)butanaMide;2(S)-[2-Oxo-4(R)-propylpyrrolidin-1-yl]butyramide;(2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide;API-Anti Epilepsy;brivaracetam
CAS NO: 357336-20-0
Molecular Weight: 703.83
Molecular Formula: C33H41N3O10S2
Boiling Point: 409.3±28.0 °C at 760 mmHg
Melting point: 76.38°
Density: 1.062
Appearance: White to Off-White Solid
Applications: Brivaracetam is indicated for the treatment of partial-onset seizures in patients 4 years of age and older. It provides a new monotherapy treatment option for epilepsy patients 16 years of age and older who suffering partial-onset[focal] seizures, which can be initiated at a therapeutic dose at day one.
Solubility: DMSO (Slightly), Methanol (Slightly)
Storage: Refrigerator

brivaracetam mechanism of action/how does brivaracetam work

Brivaracetam acts by binding to the synaptic vesicle glycoprotein 2A (SV2A), which is found throughout the brain. It has a significantly higher affinity for SV2A compared to levetiracetam, a related medication. Evidence suggests that racetams, including levetiracetam and brivaracetam, can enter the inside of recycling synaptic vesicles during the process of vesicular endocytosis. This mechanism allows them to potentially reduce the release of excitatory neurotransmitters and enhance synaptic depression when there is high-frequency activity in the brain, such as during epileptic seizures. In simpler terms, brivaracetam binds strongly to SV2A and may affect the way neurotransmitters are released in the brain, helping to control seizures.

brivaracetam reviews

  • When initiating therapy, gradual dose escalation is not required; following initiation, dose should be adjusted based on clinical response and tolerability.
  • Tablets, oral solution and injection can be used interchangeably.

brivaracetam vs levetiracetam/brivaracetam and leviracetam

Brivaracetam (BRV) belongs to the racetam group of antiepileptic drugs (AEDs) and was developed as a derivative of the related racetam medication levetiracetam (LEV). These drugs share a similar mechanism of action by selectively and strongly binding to a protein called synaptic vesicle protein 2A (SV2A). However, they may have distinct pharmacological characteristics that set them apart. In simpler terms, both brivaracetam and levetiracetam are AEDs in the racetam group. They work in a similar way by binding to a specific protein in the brain. However, they may have different effects and properties.

brivaracetam half life

Brivaracetam exhibits linear pharmacokinetics over a wide dose range, is rapidly and completely absorbed after oral administration, has an elimination half-life of seven to eight hours.

brivaracetam uses

Brivaracetam is used to treat partial-onset seizures with or without secondary generalisation, in combination with other antiepileptic drugs.

Additional information

Melting Point


Boiling point 

409.3±28.0 °C(Predicted)




DMSO (Slightly), Methanol (Slightly)






There are no reviews yet.

Be the first to review “Brivaracetam CAS 357336-20-0”

error: Alert: Content is protected !!